Search
EHA Issues Recommendations on Mild to Moderate Bleeding Disorders
HemaSphere presents first in a series of Consensus Reports on Diagnosis of Inherited Bleeding Problems
For hematologists, it can be challenging to make the correct diagnosis in patients with bleeding problems – or even to determine whether there is any bleeding…
Meeting report | HOPE ASIA 2019 Kolkata
The first edition of the Highlights of Past EHA (HOPE) in Asia was held in Kolkata, India and was a great success.
Read moreChallenging the safety of conformity: Better poster design to disseminate scientific knowledge fast
“Congratulations – your abstract was accepted for the upcoming EHA congress”.
Read moreEHA24 is YOUR congress – here’s how you can make the most of it
Congress season is an exciting time for any field. It’s a time when experts come together to share the latest developments, and also an opportunity to see friends and colleagues who you haven’t seen in a while.
Read more“Science is all about synergy” - Francesca Vinchi, woman in hematology/EHA volunteer
This Women’s History Month, we are putting the spotlight on women in hematology. One of them is Francesca Vinchi, also an EHA Volunteer.
Read moreThe 3rd EHA-ISHBT Hematology Tutorial on Lymphoproliferative and Plasma Cell Disorders
The 3rd EHA-ISHBT Hematology Tutorial on Lymphoproliferative and Plasma Cell Disorders was held on February 16-18 in Lucknow, India, and chaired by Dr AK Tripathi (King George’s Medical University, Lucknow, India) and Prof G Gaidano (University of Eastern Piedmont, Novara,…
Read moreEHA-SWG Scientific Meeting on Shaping the Future of Mesenchymal Stromal Cells Therapy
The EHA-SWG Scientific Meeting on Shaping the Future of Mesenchymal Stromal Cells Therapy brought together basic science, as well as translational and clinical research on November 23-25, 2017 in Amsterdam, The Netherlands.
Read moreSGN-CD33A Combined with Hypomethylating Therapy Produces High Remission Rates among Older Patients with AML
Acute myeloid leukemia (AML) is an aggressive form of blood cancer in which the majority of cases express CD33 on the surface of the leukemia cells.
Read moreKiller antibodies against AML
Most patients with acute myeloid leukemia (AML) can only be cured when a stem cell transplant induces an immune response against the patient’s leukemia.
Read moreImproved survival for adult Acute Lymphoblastic Leukemia (ALL) patients
Historical survival for patients 18-45 years with ALL is approximately 40 %. However the event free survival for ALL patients 18-45 years has improved to 73% following implementation of the NOPHO ALL2008 protocol in July 2008.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- »